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Accelerated apoptosis characterizes cyclosporine-associated interstitial
fibrosis. Recently we developed a model of cyclosporine nephropathy in
rats characterized by tubulointerstitial (TI) injury, macrophage infiltra-
tion, and progressive interstitial fibrosis [1, 2]. To determine if the TI
injury accompanying cyclosporine A (CsA) nephropathy was associated
with accelerated apoptosis and ischemia, we treated rats for five weeks
with CsA with or without losartan (to block angiotensin II type 1
receptor), or hydralazine/furosemide (H/F) (protocol #1). In protocol #2,
rats received CsA with or without L-NAME (to block nitric oxide) or
L-arginine (to provide a precursor to nitric oxide formation). Cyclosporine
A treated rats had increased apoptosis of tubular and interstitial cells
documented by PAS, propidium iodide staining, TUNEL assay, and
electron microscopy compared to vehicle treated controls. Macrophages
containing apoptotic cells could be confirmed by TUNEL/ED-1 double-
staining and colocalized in areas of TI injury. Animals treated with CsA 1
losartan had a statistically significant decrease in apoptosis (TUNEL 1
cells/mm2) when compared to CsA treated animals (6.0 vs. 19.9, P #
0.0001). The decrease in apoptosis in the CsA 1 H/F group was not
statistically significant. Animals treated with CsA 1 L-NAME had a
statistically significant increase in apoptosis compared to the CsA treated
animals (12.3 vs. 6.4, P 5 0.001). L-arginine administration with CsA
resulted in a decrease in tubulointerstitial apoptosis versus CsA treated
animals, however, this did not reach statistical significance. The addition
of L-arginine did result in a significant reduction in interstitial fibrosis
(P , 0.0001). Regression analysis revealed a significant correlation
between apoptosis and interstitial fibrosis in both protocols. (CsA vs. CsA
1 losartan r 5 0.63, P , 0.0001; CsA vs. CsA1 L-NAME r 5 0.83, P ,
0.0001). We conclude that CsA nephropathy is associated with a marked
increase in apoptosis of tubular and interstitial cells. Cyclosporine A
induced apoptosis is partially mediated by angiotensin II and nitric oxide
inhibition, suggesting a role for renal ischemia in this process, and CsA
induced apoptosis correlates with interstitial fibrosis.
Cyclosporine A (CsA) has revolutionized the field of organ
transplantation and is now widely used in the treatment of many
autoimmune diseases [3–5]. Despite these advances, CsA is
associated with major renal complications including acute neph-
rotoxicity, chronic tubulointerstitial fibrosis, and rarely hemolytic
uremic syndrome [6–8]. Although acute cyclosporine nephrotox-
icity due to intense renal vasoconstriction is reversible, chronic
tubulointerstitial nephropathy is generally considered to be irre-
versible and occasionally progressive. Recently we developed a
model of chronic CsA nephropathy in rats that has remarkable
similarities to CsA nephropathy in humans [1]. Specifically, rats
given CsA on a low salt diet develop both the characteristic
arterial lesion (hyalinosis of the afferent arteriole) and striped
interstitial fibrosis that is observed with chronic CsA nephrotox-
icity in humans [2, 9, 10]. The model is characterized by early
tubular injury with both tubular and interstitial cell proliferation,
extracellular matrix deposition, and the infiltration of monocyte/
macrophages into the interstitium in association with tubular
expression of the macrophage adhesive protein, osteopontin [2,
9]. Despite this initial proliferation, over time there is a progres-
sive loss of cellularity in the areas of interstitial fibrosis [9]. This
has suggested to us that there may be an imbalance in which a loss
of cells may be occurring via apoptosis that is in excess of the
proliferative response to replace them. To investigate this hypoth-
esis, as well as the possibility that CsA-induced renal ischemia
may be contributing to this process, we explored the role apopto-
sis plays in the pathogenesis of tubulointerstitital fibrosis in
experimental CsA nephropathy. To further define the role of
renal ischemia in this model, we studied the two vasoactive
mediators: angiotensin II and nitric oxide.
METHODS
Experimental protocol
Studies were designed to determine if the tubulointerstitial
fibrosis that occurs secondary to CsA is associated with acceler-
ated apoptosis and to determine the role of angiotensin II (Ang
II) and nitric oxide (NO) in this process. Two separate experi-
ments were conducted. The first experiment (protocol #1) was
designed to determine if chronic CsA nephrotoxicity is associated
with accelerated apoptosis, and to examine the effect of blocking
the angiotensin II type 1 receptor in this process. An additional
group was administered hydralazine/furosemide to block CsA-
associated vasoconstriction through an Ang II-independent mech-
anism. Analysis of these animals as it related to the development
of hyalinosis and tubulointerstitial fibrosis has been previously
reported by Pichler et al [9]
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Protocol #1. (N 5 49) [9].
(1) CsA. Rats received a daily s.c. injection of CsA, 15 mg/kg for
35 days (N 5 8).
(2) CsA 1 losartan (L). Rats received daily CsA, 15 mg/kg by
s.c. injection, and losartan, 10 mg/kg by gavage, for 35 days (N 5
7).
(3) CsA 1 hydralazine/furosemide (H/F). Rats received daily
CsA, 15 mg/kg by s.c. injection, a s.c. injection of furosemide at a
dose of 1 to 2 mg/kg q.o.d., and hydralazine, 240 mg/liter in the
drinking water, for 35 days (N 5 9).
(4) Vehicle (VH). Rats received a daily s.c. injection of olive oil,
1 ml/kg, for 35 days (N 5 8).
(5) Vehicle (VH) 1 losartan (L). Rats received a daily sc
injection of olive oil, 1 ml/kg, and losartan, 10 mg/kg by gavage for
35 days (N 5 8).
(6) Vehicle (VH) 1 hydralazine/furosemide (H/F). Rats re-
ceived a daily s.c. injection of olive oil, 1 mg/kg, a s.c. injection of
furosemide at a dose of 1 to 2 mg/kg q.o.d., and hydralazine, 240
mg/liter in the drinking water, for 35 days (N 5 9).
Protocol #2 (N 5 31). In the second experiment (protocol #2)
the effect of modulating NO production on CsA nephropathy and
apoptosis was assessed by administering L-NAME (to block NO),
and L-arginine (to serve as a precursor of NO). Because L-NAME
is known to exacerbate tubulointerstitial injury independent of
cyclosporine [11–13], half of the CsA dose (7.5 mg/kg/day) was
chosen for protocol #2.
(1) CsA. Rats received CsA a daily s.c. injection of CsA, 7.5
mg/kg/day for 28 days (N 5 7).
(2) CsA 1 L-Arg. Rats received daily CsA, 7.5 mg/kg/day s.c. 3
28 days and L-Arg at a dose of 1.7 g/kg/day added in powdered
form to a daily preweighed diet (N 5 7).
(3) CsA 1 L-NAME. Rats received daily CsA (7.5 mg/kg/day
s.c. 3 28 days) and L-NAME dissolved in distilled water at a
concentration of 5 mg/100 ml (N 5 5).
(4) VH 1 L-Arg. Rats received daily weight-based equivalent
volumes of olive oil vehicle in place of CsA and L-Arg 1.7 g/kg/day
added in powder form to daily preweighed diet (N 5 6).
(5) VH 1 L-NAME. Rats received daily weight-based equiva-
lent volumes of olive oil vehicle in place of CsA and were allowed
free access to L-NAME solution dissolved in distilled water at a
concentration of 5 mg/100 ml (N 5 6).
Animals
Adult male Sprague-Dawley rats (Charles River, Wilmington,
MA, USA; protocol #1, N 5 49, 225 to 250 g; protocol #2, N 5
31, 200 to 250 g) were housed in individual cages in a temperature
and light controlled environment. All rats received a low-salt diet
(0.05% sodium; Teklad, Madison, WI, USA) [9]. After one week
on the low-salt diet, weight matched rats (protocol #1) and age
matched (protocol #2) rats were randomly assigned to the above
listed treatment groups.
Drugs
In protocol #1, CsA provided by Sandoz Research Institute
(East Hanover, NJ, USA) was diluted in olive oil at to a final
concentration of 15 mg/ml. Losartan (L), provided by Cardiovas-
cular Diseases Research (Du Pont Merck Pharmaceutical Com-
pany, Wilmington, DE, USA), was dissolved in sterile water to a
final concentration of 10 mg/ml. Hydralazine (H) (Sigma Chem-
ical Co., St. Louis, MO, USA) was dissolved in the animals’
drinking water to a concentration of 240 mg/liter. Furosemide (F)
(Lympho Med Inc., Rosemont, IL, USA) was dissolved in sterile
water to a final concentration of 1 mg/ml [9].
In protocol #2, the CsA (Sandoz) at a dose of 7.5 mg/kg/day
administered by s.c. injection. L-NAME (Sigma) at a dose of 5
mg/100 ml added to the drinking water.
Blood and urine analysis (protocol #2)
Whole blood CsA levels were measured by radioimmunoassay
(angiotensin I-Biotecx radioimmunoassay; Biotecx Laboratories,
Houston, TX, USA). Serum creatinine was measured by a Cobas
autoanalyzer (Roche Diagnostics, Div. Hoffman-La Roche, Nut-
ley, NJ, USA).
Blood pressure measurement (protocol #2)
Tail cuff blood pressure was measured at baseline and at the
end of the protocol using the Natsume KN 210-1 manometer-
tachometer (Peninsula Laboratories, Inc., Belmont, CA, USA).
Rats in a conscious, restrained state were placed on a pre-warmed
platform of 37°C prior to blood pressure measurement. An
average of five blood pressure (BP) measurements were recorded
after a stable heart rate was demonstrated.
Renal morphology
Renal biopsies were fixed in Methyl Carnoy’s solution and
embedded in paraffin [14]. Four micron sections were stained with
periodic acid-Schiff’s reagent (PAS) and counterstained with
hematoxylin to determine the degree of interstitial fibrosis.
Interstitial fibrosis was scored semiquantitatively by a blinded
observer who examined cortical tubulointerstitial fields on PAS-
stained renal biopsies using the 203 objective. A minimum of 30
fields were assessed in each biopsy. The following semiquantita-
tive score was used: Score 0, normal interstitium and tubules;
Score 1, mild fibrosis with minimal interstitial thickening between
the tubules; Score 2, modest fibrosis with moderate interstitial
thickening between the tubules; Score 3, severe fibrosis with
severe interstitial thickening between the tubules [9]
Apoptosis
Apoptosis was identified by four methods. On light microscopy
(PAS), apoptotic cells were identified by their dense nuclei and
loss of cytoplasm. Apoptotic cells were also identified by pro-
pidium iodide by their typical pyknotic nuclei [15]. Apoptotic cells
were additionally identified by the TUNEL assay, which labels
cells with oligonucleosomal chromatin cleavage typical of apopto-
sis [16]. Finally, confirmaton of apoptosis was performed by
electron microscopy which displayed condensation of nuclear
heterochromatin characteristic of cells undergoing apoptosis [17,
18].
TUNEL assay
Apoptotic cells were detected in tissue sections by the TUNEL
assay as previously described [16]. Briefly, 4 micron formalin fixed
sections were deparaffinized and rehydrated in ethanol, followed
by an antigen retrieval step using boiling citric acid (pH 5 6.0, 10
mM). Samples were incubated in proteinase K (6.2 mg/ml; Boehr-
inger Mannheim, Indianapolis, IN, USA), followed by Tdt (300
enzyme units/ml; Pharmacia Biotech, Alameda, CA, USA), and
Bio-14-dATP (0.94 nm; Gibco BR, Grand Island, NY, USA).
Biotinylated ATP was detected using the Vectastain Elite ABC
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peroxidase staining kit (Vector Laboratories Inc, Burlingame,
CA, USA; following the manufacturer’s protocol). As a positive
control, slides were treated with DNAse (20 Kunitz units/ml;
Sigma). The slides for the negative control were treated with
buffer lacking TdT.
Staining for apoptosis by the TUNEL reaction was performed
on 49 biopsies from protocol #1, and 31 biopsies in protocol #2.
Quantitation of TUNEL positive cells was performed in the
glomeruli and the tubulointerstitium. The number of positive cells
per glomeruli was based on counting the total number of glomer-
uli per biopsy. The number of TUNEL positive cells within the
tubulointerstitium of each biopsy was calculated in a blinded
fashion by counting the total number of positive cells in 30
sequentially selected 0.50 mm2 grids in the renal cortex at 1003
magnification excluding the medulla. To further quantitate which
population of cells were undergoing apoptosis, the number of
TUNEL positive tubular, intratubular, and interstitial cells in 30
sequentially selected 0.125 mm2 grids at 4003 magnification were
counted. The number of TUNEL 1 cells at 1003 magnification
and 4003 magnification were then converted to a value per mm2
by dividing the number of TUNEL positive cells/(30 fields 3 area
of grid). The number of interstitial, tubular and intratubular
TUNEL positive cells/mm2 are expressed as mean TUNEL pos-
itive cells/mm2 per animal group, and as a percentage of the total
number of cells quantitated at 4003. Biopsies with no TUNEL
positive cells at 4003 magnification were deleted in calculating
these percentages.
TUNEL/macrophage double staining
To determine if there was a relationship between the TUNEL
positive cells and the presence of macrophages, TUNEL and
macrophage double staining was performed on formalin fixed
tissue using the TUNEL protocol given above. Following the
TUNEL procedure, biopsies were washed in PBS 3 3 five
minutes, followed by 2% BSA in water block for 10 minutes at
room temperature. Monocyte-macrophages were then labeled
with the mouse monoclonal ED-1 (1:100) (Serotec, Indianapolis,
IN, USA). Tissues were incubated at 4°C overnight. The following
day the biopsies were washed in PBS 3 3 five minutes, and a
peroxidase rat anti-mouse IgG1(1:50) secondary antibody (Zymed
Laboratories Inc., San Francisco, CA, USA) was applied for 60
minutes at room temperature. Following a final PBS wash 3 3 five
minutes, the biopsies were placed in diaminobenzidine at 37°C to
which nickel chloride and hydrogen peroxide had been added for
10 minutes. Tissues were counterstained in methyl green and
dehydrated in graded ethanols.
Fig. 1. Cyclosporine associated interstitial fibrosis. Photomicrographs
show, light microscopy (PAS) of a vehicle treated rat (a) and a rat that
received CsA (15 mg/kg/day 3 35 days; b). The biopsy of the CsA treated
animal reveals tubular injury, inflammatory cell infiltration, extracellular
matrix deposition (a and b magnification 3400).
Table 1. Systemic parameters for protocol #1 [9]
Groups
D Body wt
g
GFR
ml/min/100 g
Serum creatinine
(mg/dl) day 35
SBP
mm Hg
CsA 82.1 6 10.2 0.21 6 0.04 0.87 6 0.08 120 6 6
CsA 1 L 28.0 6 9.7a 0.17 6 0.04b 1.63 6 0.27c 80 6 4c
CsA 1 H/F 226.6 6 10.6a 0.31 6 0.05 0.85 6 0.23 95 6 3c
VH 132.8 6 6.4a 0.52 6 0.03c 0.39 6 0.01a 133 6 6
VH 1 L 101.4 6 15.6 0.47 6 0.04 0.48 6 0.08 92 6 6
VH 1 H/F 14.1 6 12.6 0.53 6 0.03 0.42 6 0.02 115 6 5
Values are expressed as mean 6 SE. Abbreviations are: CsA, treatment
with cyclosporine A (15 mg/kg/day); CsA 1 L, CsA 1 (10 mg losartan/kg);
CsA 1 H/F, CsA 1 hydralazine (240 mg/liter) and furosemide (1–2
mg/kg/q.o.d.); VH, vehicle treatment (1 ml olive oil/kg); VH 1 L, vehicle
treatment 1 (10 mg of losartan/kg); VH 1 H/F, vehicle treatment 1
hydralazine (240 mg/liter) and furosemide (1–2 mg/kg/q.o.d.); GFR,
glomerular filtration rate; SBP, systolic blood pressure.
a P , 0.05 vs. CsA
b P , 0.007 vs. CsA 1 H/F
c P , 0.005 vs. CsA
Table 2. Systemic parameters for protocol #2
Groups
D Body wt
g
GFR
ml/min/100 g
Serum
creatinine
(mg/dl)
Day 28
SBP
mm Hg
CsA 130.7 6 11.5b 0.24 6 0.02 0.84 6 0.06a 143.7 6 3.6a
CsA 1 L-Arg 125.0 6 10.6c 0.31 6 0.03b 0.80 6 0.05a 144.0 6 3.4a
CsA 1 L-NAME 55.8 6 28.1 0.12 6 0.04 2.39 6 0.60 171.8 6 4.9
VH 1 L-Arg 158.4 6 7.8a 0.36 6 0.03a 0.67 6 0.11a 133.7 6 2.1a,e
VH 1 L-NAME 157.2 6 4.9a 0.30 6 0.02d 0.64 6 0.02a 158.0 6 3.4
Values are expressed as mean 6 SE. Abbreviations are: CsA, treatment
with cyclosporine A (7.5 mg/kg/day); CsA 1 L-Arg, CsA 1 (1.7 g/kg/day
L-arginine added to daily diet); CsA 1 L-NAME, CsA 1 (5 mg/100 ml
L-NAME drinking water); VH 1 L-Arg, (weight based equivalent volume
of olive oil 1 L-Arg 1.7 g/kg/day); VH 1 L-NAME, vehicle 1 (5 mg/100
ml L-NAME added to drinking water); GFR, glomerular filtration rate;
SBP, systolic blood pressure.
a P , 0.0001 vs. CsA 1 L-NAME
b P 5 0.0005 vs. CsA 1 L-NAME
c P 5 0.0012 vs. CsA 1 L-NAME
d P 5 0.0009 vs. CsA 1 L-NAME
e P , 0.0001 vs. VH 1 L-NAME
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Apoptosis was also confirmed by propidium iodide staining of
Methyl Carnoy’s fixed tissue as previously described [15]. Tissue
for electron microscopy (EM) was fixed in half-strength Kar-
novsky’s solution (1% paraformaldehyde and 1.25% glutaralde-
hyde in 0.1 M Na cacodylate buffer, pH 7.0), post-fixed in osmium
tetroxide, dehydrated in graded ethanols, and embedded in epoxy
resin. Thin sections were stained with uranyl acetate and lead
citrate and examined with a Philips 410 (Philips Export BV,
Eindhoven, The Netherlands) [17].
Statistical analysis
All values are expressed as mean 6 SE, unless otherwise stated.
Statistical significance (P value # to 0.05) was established using
the Student’s t-test or one way analysis of variance with modified
t-test performed using the Bonferroni correction [19].
RESULTS
Physiologic studies in protocol #1
The final body wt of all CsA-treated rats (regardless of their
treatment with L or H/F) was was significantly lower compared
with that of vehicle controls [9], whereas vehicle-treated animals
gained 133 g during the 35 days of the study. CsA 1 L rats lost 8 g
and CsA 1 H/F-treated animals lost a mean of 27 g. These data
are shown in Table 1.
Renal function. Renal function (GFR) in the different groups is
summarized in Table 1. All CsA-treated animals had a significant
reduction in GFR as measured by creatinine clearance. Animals
treated with CsA 1 H/F had a significantly higher GFR compared
with those treated with CsA 1 L. There was no significant
difference between CsA and CsA 1 H/F.
Systolic blood pressures. Table 1 summarizes the systolic blood
pressure (SBP) data of the various groups. CsA treatment alone
resulted in a slight but not significant reduction in SBP compared
Fig. 2. Apoptosis in cyclosporine A (CsA) nephropathy. Photomicrographs show, cyclosporine (15 mg/kg/day) mediated apoptosis as shown by light
microsopy (PAS). Characteristic apoptotic tubular epithelial cells are shown in a and b (marked by the arrows). An apoptotic interstitial cell is shown
in c (marked by the arrow). Note the characteristic condensed chromatin consistent with apoptotic cells. Panel d reveals apoptosis of two adjacent
tubular epithelial cells identified by their condensed homogenous chromatin within their nuclei by propidium iodide staining (marked by arrows) (a-c,
magnification 31000; d 3630).
Fig. 3. Electron micrograph of an apoptotic tubular cell in cyclosporine
A (CsA) nephropathy. Electron micrograph of a renal tubular epithelial
cell exposed to CsA (15 mg/kg/day) reveals apoptosis with condensation of
nuclear heterochromatin apposed to the nuclear membrane (marked by
the arrow; magnification 34800).
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with vehicle-treated animals. Both treatments (CsA 1 H/F, CsA
1 L) significantly reduced SBP compared with animals treated
with CsA alone.
Physiologic studies in protocol #2
The final body wt of all CsA-treated rats (regardless of their
treatment with L-Arg, or L-NAME) was significantly lower com-
pared with that of vehicle treated controls. Vehicle treated
animals treated with L-Arg or L-NAME gained essentially the
same 158 g during the 28 days of the study. CsA treated rats
gained a mean of 130.7 g, CsA 1 L-Arg treated rats gained a
mean of 125 g, and CsA 1 L-NAME treated rats demonstrated
the least weight gain (55.8 g) among animal groups. These data
are shown in Table 2.
Renal function. Renal function (glomerular filtration rate;
GFR) in the different animal groups is summarized in Table 2.
Animals treated with CsA and CsA 1 L-NAME had a reduction
in GFR as measured by creatinine clearance compared to both
vehicle-treated control animal groups and the CsA 1 L-Arg
group. The most significant decrease in GFR was observed in the
CsA 1 L-NAME group. Although there was a decline in GFR in
the CsA treated group, it was not statistically significant. The
addition of L-Arg improved GFR in CsA treated animals, but this
did not reach statistical significance.
Systolic blood pressures. Table 2 summarizes the SBP data of the
various groups. Animals in the CsA 1 L-NAME and VH 1
L-NAME demonstrated significantly elevated blood pressures
compared to all other animal groups (171.8 and 158.0, respective-
ly). The addition of L-arginine had no effect on the mean blood
pressure of animals receiving CsA. Animals in the VH 1 L-Arg
group demonstrated the lowest systolic blood pressures, which
were significantly reduced compared to animals in the CsA 1
L-NAME and VH 1 L-NAME groups.
Cyclosporine A nephropathy is associated with increased
tubulointerstitial apoptosis
We have previously reported that the administration of CsA to
rats on a low salt diet will result in afferent arteriolar hyalinosis
and progressive TI fibrosis [2, 9, 10]. Figure 1a depicts a renal
biopsy from a vehicle treated rat and Figure 1b shows a represen-
tative biopsy from a rat that received CsA (15 mg/kg/day). Rats
treated with CsA for 35 days demonstrate marked tubular dilata-
tion and extracellular matrix deposition. To determine if apopto-
sis was associated with interstitial fibrosis, we examined apoptosis
by light microscopy (PAS), propidium iodide, TUNEL assay and
electron microscopy. The administration of CsA (15 mg/kg/day in
protocol #1) was associated with a remarkable increase in the
number of apoptotic cells in the tubulointerstitium. By light
microscopy, apoptotic cells manifested the characteristic nuclear
condensation and loss of cytoplasm (Fig. 2 a-c). Confirmation of
apoptosis was also performed by propidium iodide, which stains
all cell nuclei, but identifies apoptotic nuclei by their typical
pyknotic appearance (Fig. 2d). To further support the presence of
apoptosis, electron microscopy verified the characteristic con-
densed heterochromatin of apoptotic nuclei (Fig. 3).
To quantitate the degree of apoptosis the TUNEL assay was
performed, which detects cleaved DNA that is formed by the
activation of the DNA polymerase during apoptotic cell death
[20–25]. As shown in Table 3, occasional apoptotic cells were
Table 3. Mean number of TUNEL positive tubulointerstitial cells/mm2 per animal group
#
Animals
Mean
TUNEL 1
cells/mm2
SE
TUNEL 1
cells/mm2
% Interstitiala % Tubulara % Intratubulara
TUNEL 1 cells/mm2
(mean # cells/mm2)
Protocol #1b
CsA 8 19.9 2.6 60.2% (44.3) 15.9% (11.7) 23.8% (17.5)
CsA 1 L 7 6.0d 0.41 67.2% (12.4) 23.3% (4.2) 7.7% (1.4)
CsA 1 H/F 9 12.9 3.5 67.1% (35.7) 29.5% (15.7) 3.4% (1.8)
Vehicle 8 4.3d,f 0.49 81.5% (10.6) 13.8% (1.8) 4.6% (0.6)
VH 1 L 8 3.5d,f 0.65 53.5% (5.3) 14.1% (1.4) 32.3% (3.2)
VH 1 H/F 9 1.8d,e 0.62 53.8% (4.9) 7.6% (0.7) 38.6% (3.5)
Protocol #2c
CsA 7 6.4h 1.7 75.2% (16.4) 18.2% (3.9) 6.8% (1.5)
CsA 1 L-Arg 7 2.2g 0.26 64.0% (8.1) 33.2% (4.2) 2.7% (.35)
CsA 1 NAME 5 12.3 2.0 47.7% (22.6) 27.9% (13.2) 24.3% (11.5)
VH 1 L-Arg 6 1.6g 0.38 65.2% (6.9) 9.8% (1.0) 24.8% (2.6)
VH 1 L-NAME 6 1.6g 0.16 66.2% (7.4) 27.5% (3.1) 6.2% (0.7)
Mean TUNEL 1 cells/mm2 quantitated at 1003 magnification; statistics based on 1003 values. Mean % Interstitial, % Tubular, % Intratubular
values quantitated at 4003 magnification.
a Values are expressed as mean (SE).
b CsA, treatment with CsA (15 mg/kg/day); CsA 1 L, CsA 1 (10 mg losartan/kg); CsA 1 H/F, CsA 1 hydralazine (240 mg/liter) and furosemide (1–2
mg/kg/q.o.d.); VH, vehicle treatment (1 ml olive oil/kg); VH 1 L, vehicle treatment 1 (10 mg of losartan/kg); VH 1 H/F, vehicle treatment 1
hydralazine (240 mg/liter) and furosemide (1–2 mg/kg/q.o.d.).
c CsA, treatment with CsA (7.5 mg/kg/day); CsA 1 L-Arg, CsA 1 (1.7 g/kg/day L-Arg added to daily diet); CsA 1 L-NAME, CsA 1 (5 mg/100 ml
L-NAME drinking water); VH 1 L-Arg, (weight based equivalent volume of olive oil 1 L-Arg 1.7 g/kg/day); VH 1 L-NAME, vehicle 1 (5 mg/100 ml
L-NAME added to drinking water).
d P , 0.0001 vs. CsA (15 mg/kg/day)
e P 5 0.0001 vs. CsA (15 mg/kg/day) 1 H/F
f P , 0.05 vs. CsA (15 mg/kg/day) 1 H/F
g P , 0.0001 vs. CsA (7.5 mg/kg/day) 1 L-NAME
h P 5 0.0017 vs. CsA (7.5 mg/kg/day) 1 L-NAME
Thomas et al: Cyclosporine nephropathy and apoptosis 901
present in the vehicle treated control animals (protocol #1; Fig.
4a). However, a remarkable increase in the number of apoptotic
cells were present in the tubules and in the interstitium in the CsA
treated animals (protocol #1, 15 mg/kg/day; Table 3 and Fig. 4b).
Interestingly, lower doses of CsA (protocol #2, 7.5 mg/kg/day)
were associated with an intermediate level of apoptosis (Table 3).
Whereas an increase in apoptotic cells was noted in the tubules
and in the interstitium, when all groups were compared from both
protocols, the number of glomerular TUNEL positive cells was
not statistically significant.
The observation that there is apoptosis of interstitital cells
raised the possibility that apoptosis could be involving interstitial
fibroblasts or infiltrating macrophages. To further pursue this
issue, we performed double staining to look for the presence of
macrophages and apoptotic cells. As shown in Figure 5a, the
presence TUNEL positive cells and macrophages (by ED-1 stain,
shown in yellow) frequently colocalized in areas of tubulointersti-
tial injury. This suggests that the macrophages are either under-
going apoptosis themselves or they are aiding in the clearance of
apoptotic cells. Support for this latter possibility is shown in
Figure 5b, which shows a macrophage with an intact nucleus
containing TUNEL 1 material in its cytoplasm. Figure 5 c and d
also reveal macrophages with noncondensed cytoplasms contain-
ing TUNEL 1 cells. Clear identification of intact macrophage
nuclei are more difficult to identify in Figure 5 c and d; however,
macrophage apoptosis would be accompanied with cytoplasmic
Fig. 4. Apoptosis in cyclosporine A (CsA) nephropathy by the TUNEL assay. Photomicrographs show apoptosis as detected by the TUNEL assay. (a)
A vehicle treated animal, compared to the biopsy of a rat that received CsA (15 mg/kg/day; b). Note the marked increase in TUNEL positive cells in
the CsA treated rat (marked by arrows). (c) A CsA (15 mg/kg/day) photomicrograph at a higher power. (d) A rat that received CsA (15 mg/kg/day) 1
losartan. Note the decreased number of TUNEL positive cells in the losartan treated group (marked by arrows). (e) A rat that received CsA (7.5
mg/kg/day). (f) A rat that received CsA (7.5 mg/kg/day) 1 L-NAME. Note the increased number of TUNEL positive cells in the CsA 1 L-NAME
treated rat (marked by arrows) (a and b magnification 3200; c-f 3400).
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shrinkage, indicating that the origin of the TUNEL 1 cells in
these Figures are not macrophages.
Role of angiotensin II type 1 receptor blockade in apoptosis in
protocol #1
Studies were performed to examine the role of Ang II in CsA
induced apoptosis. Because losartan blocks Ang II-mediated
vasocontriction, which has been proposed to play a role in CsA
mediated tubulointerstitial injury [9], a CsA 1 H/F group was
used as another means to block vasoconstriction independent of
Ang II. As shown in Table 3, animals in the CsA 1 L group had
a greater than 50% decrease in the degree of apoptosis when
compared to CsA treated animals (P # 0.0001). Animals in the
CsA 1 L group had a mean of 6.0 TUNEL positive cells/mm2
versus 19.9 in the CsA group (Fig. 4 c, d). Losartan also resulted
in a statistically significant reduction in the degree of interstitial
fibrosis (P 5 0.001; Table 4) [9]. Although there was a reduction
in the number of TUNEL positive cells in the CsA 1 H/F group,
the difference was not statistically significant. This may be due to
the fact that two of the nine biopsies from rats treated with CsA
1 H/F had large focal areas of TUNEL 1 cells in their biopsies as
reflected by the standard error from the mean in this group. These
focal patches may represent areas of necrosis, since DNA frag-
mentation as detected by the TUNEL assay also occurs in cellular
necrosis [26]. As shown in Figure 6, the two animals with the
higher mean number of TUNEL 1 cells/mm2 had a similar degree
of interstitial fibrosis as the other seven animals in the CsA 1 H/F
group, as well as vehicle treated animals. This would suggest that
some of the cells in these two animals were necrotic, and not
contributing to the development of interstitial fibrosis. The addi-
tion of H/F to CsA (15 mg/kg/day) versus CsA reduced the degree
of interstitital fibrosis (P , 0.0001) as previously reported by
Pichler et al [9].
The predominant lesion in CsA nephropathy is interstitial
fibrosis. In order to examine the relationship between interstitial
fibrosis and apoptosis in this model, we performed a regression
analysis between TUNEL 1 cells/mm2 and interstitial fibrosis in
protocol #1. As shown in Figure 6, there is statistically significant
correlation between mean TUNEL 1 cells/mm2 and interstitial
fibrosis score [0–3] in animals receiving CsA (15 mg/kg/day)
versus CsA 1 L, CsA 1 H/F, vehicle, vehicle 1 L and vehicle 1
H/F (r 5 0.63, P , 0.0001).
Role of nitric oxide blockade in apoptosis in protocol #2
We also examined the role of nitric oxide inhibition and NO
generation in the CsA model. As shown in Table 3, animals
treated with CsA 1L-NAME had a 100% increase in the number
of TUNEL positive tubulointerstitial cells compared to CsA
treated animals (12.3 vs. 6.4 mean TUNEL positive cells/mm2,
respectively, P 5 0.001; Fig. 4 e, f). Consistent with the increase in
apoptosis in the CsA 1 L-NAME group was a statistically
significant increase in the degree of interstitial fibrosis (P 5 0.001)
Fig. 5. Apoptotic cells and macrophages colocalize in CsA nephropathy. Photomicrographs show the results of TUNEL/ED-1 (macrophage) double
staining. (a) The presence of apoptotic cells (by TUNEL reaction shown in black) and macrophages (by ED-1 stain, shown in yellow) is frequently
colocalized in areas of tubulointerstitial injury. (b) An intratubular macrophage with an intact green nucleus marked by the thick black arrow engulfing
an apoptotic cell marked by the thin black arrow. (c and d) Apoptotic cells that have been engulfed by a macrophages. The macrophage nuclei are less
easily visualized in c and d (magnification in a 3400; b-d 31000).
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versus CsA treated animals (P , 0.0001), versus vehicle 1
L-NAME treated animals, as shown in Table 4. The administra-
tion of L-Arg in addition to CsA resulted in a reduction in the
mean number of TUNEL 1 cells compared to CsA treated
animals; however, this did not reach statistical significance. When
compared to animals treated with CsA1 L-NAME, CsA 1 L-Arg
resulted in a significant decrease in apoptosis (P , 0.0001). The
reduction in fibrosis in the CsA 1 L-Arg group was significant
when compared to CsA treated (P 5 0.001) and CsA 1 L-NAME
(P , 0.0001) treated animals. Animals in the VH 1 L-NAME
group had the same mean number of TUNEL 1 cells/mm2 (1.6)
as animals in the VH 1 L-Arg group. They also had nearly
identical fibrosis scores, indicating that L-NAME was not a major
contributor to the formation of interstitial fibrosis in and of itself
in this model. Animals that received CsA (15 mg/kg/day) and CsA
(7.5 mg/kg/day) had mean apoptosis scores of 19.9 and 6.4,
respectively, and fibrosis scores of 0.8 versus 0.47, respectively,
indicating that the development of interstitial fibrosis in this
model was CsA dose dependent, was exacerbated by nitric oxide
inhibition and involved the apoptotic pathway. Similarly, the same
relationship between mean TUNEL 1 cells/mm2 and interstitial
fibrosis score was found in (protocol #2). As shown in Figure 7,
there is a statistically significant correlation between mean
TUNEL 1 cells/mm2 and interstitial fibrosis score (0 to 3) in
animals receiving CsA (7.5 mg/kg/day), CsA 1 L-NAME, CsA 1
L-arginine, vehicle 1 L-arginine and vehicle 1 L-NAME (r 5
0.83, P , 0.0001).
DISCUSSION
We examined an experimental model of CsA nephropathy that
is similar to that observed in humans. In this model striped
interstitial fibrosis and arteriolar hyalinosis occur. Although tubu-
lointerstitial proliferation also characterizes renal injury mediated
by CsA [2], angiotensin II [27], and 5/6 nephrectomized rats [28],
progressive tubulointerstitial fibrosis eventually results in a hypo-
cellular lesion. The possibility that accelerated or excess apoptosis
may contribute to the pathogenesis of fibrosis prompted us to
address this issue in the model of CsA nephropathy. We also
examined if apoptosis in CsA nephropathy was mediated by NO
or Ang II, factors that could modulate CsA induced vasoconstric-
tion and ischemia.
The first major finding was that apoptosis was increased in our
model. This was confirmed by four methods including light
microscopy (PAS), propidium iodide, electron microscopy and the
TUNEL assay. The apoptosis affected the tubular and interstitial
cell populations, but not the glomeruli. Apoptosis was greatest in
the interstitial compartment, but involved tubules, and was often
concentrated in regions of fibrosis.
To further identify the apoptotic cells within the interstitium,
double labeling with a monoclonal antibody directed to macro-
phages (ED-1) and the TUNEL assay was performed. Many
TUNEL positive cells were also ED-11. In some instances it was
difficult to determine if the macrophages were undergoing apo-
ptosis, or whether the macrophages were ingesting apoptotic cells.
However, in many instances, the latter could be confirmed by the
identity within the macrophage cytoplasm of a separate intact
macrophage nucleus adjacent to a TUNEL positive cell. This is
Fig. 6. Relationship between the number of TUNEL 1 cells/mm2 versus
fibrosis: Effect of angiotensin II blockade (protocol #1). This linear
regression shows the significant correlation between apoptosis and inter-
stitial fibrosis in animals receiving CsA (15 mg/kg/day) versus CsA (15
mg/kg/day) 1 losartan (r 5 0.63, P , 0.0001). These results indicate that
apoptosis and interstitial fibrosis can be significantly reduced by losartan in
this model. Symbols are: (F) CsA 15 mg/kg/day; (E) CsA 1 H/F; (f) CsA
1 L; (M) V 1 H/F; () V 1 L; () vehicle. r 5 0.63; P , 0.0001.
Table 4. Cyclosporine associated interstitial fibrosis: Effect of
angiotensin II receptor blockade (losartan) [9] and nitric oxide
inhibition (L-NAME)
Groups
Interstitial fibrosis
(0–3)
Protocol #1b
CsA 0.8 6 0.18
CsA 1 Ld 0.36 6 0.12
CsA 1 H/Fe 0.26 6 0.05
VHe 0.0 6 0.0
VH 1 Le 0.09 6 0.05
VH 1 H/Fe 0.09 6 0.02
Protocol #2c
CsAi 0.47 6 0.09
CsA 1 L-Argf,h 0.19 6 0.03
CsA 1 L-NAME 0.79 6 0.07
VH 1 L-Argg,h 0.02 6 0.01
VH 1 L-NAMEg,h 0.01 6 0.01
a Values are expressed as mean 6 SE.
b CsA, treatment with CsA (15 mg/kg/day); CsA 1 L, CsA 1 (10 mg
losartan/kg); CsA 1 H/F, CsA 1 hydralazine (240 mg/liter) and furo-
semide (1–2 mg/kg/q.o.d.); VH, vehicle treatment (1 ml olive oil/kg);
VH 1 L, vehicle treatment 1 (10 mg of losartan/kg); VH 1 H/F, vehicle
treatment 1 hydralazine (240 mg/liter) and furosemide (1–2 mg/kg/q.o.d.).
c CsA, treatment with CsA (7.5 mg/kg/day); CsA 1 L-Arg, CsA 1 (1.7
g/kg/day L-Arg added to daily diet); CsA 1 L-NAME, CsA 1 (5 mg/100
ml L-NAME drinking water); VH 1 L-Arg, (weight based equivalent
volume of olive oil 1 L-Arg 1.7 g/kg/day); VH 1 L-NAME, vehicle 1 (5
mg/100 ml L-NAME added to drinking water).
d P 5 0.001 vs. CsA (15 mg/kg/day)
e P , 0.0001 vs. CsA (15 mg/kg/day)
f P , 0.05 vs. CsA (7.5 mg/kg/day)
g P , 0.0001 vs. CsA (7.5 mg/kg/day)
h P , 0.001 vs. CsA (7.5 mg/kg/day) 1 L-NAME
i P 5 0.001 vs. CsA (7.5 mg/kg/day) 1 L-NAME
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consistent with data by Savill and others suggesting that macro-
phages can ingest apoptotic cells [29–33]. Savill et al have shown
that phagocyte recognition of cells undergoing apoptosis is medi-
ated by an a VB3/thrombospondin recognition mechanism [25,
34–39].
A second major finding was that both the tubular and intersti-
tial cell apoptosis were mediated by Ang II, as demonstrated by
the reduction in apoptosis with losartan treatment. Previous
studies have shown that both angiotensin converting enzyme
(ACE) inhibitors [40, 41] and AT1 receptor antagonists [9, 41]
block the interstitial fibrosis in experimental CsA nephropathy.
One mechanism for this protective effect may be due to the ability
of losartan to block the afferent arteriolar hyalinosis lesion [9],
which may improve blood flow and reduce ischemia to the
interstitium. Angiotensin II also mediates vasoconstriction not
only of the efferent arteriole but also of the vasa rectae [42], and
can reduce blood flow to the peritubular capillaries [43] that
provide nutritional support to the tubules. While these studies
would suggest that losartan may act to reduce tubulointerstitial
injury and apoptosis by blocking the vasoconstrictive actions of
Ang II, the Ang II may have non-hemodynamic effects that can
promote the development of tubulointerstitial injury. Angiotensin
II has been shown to induce cell proliferation, hypertrophy, and
expression of immediate early genes (such as c-fos) and growth
factors including transforming growth factor-beta (TGF-b) and
platelet-derived growth factor (PDGF), in vascular smooth mus-
cle cells, glomerular mesangial cells and renal proximal tubular
cells [44]. In vitro studies have also shown that Ang II is capable
of affecting the production and degradation of the extracellular
matrix. It has been reported that TGF-b, in response to Ang II,
acts on glomerular epithelial cells and mesangial cells to stimulate
the production of extracellular matrix components [44]. It has also
been shown that CsA treated rats show a progressive increase in
mRNA expression of TGF-b1 and matrix proteins, and it has been
proposed that the fibrosis of chronic CsA nephropathy likely
involves the dual action of TGF-b1 on matrix deposition and
degradation [45]. Kagami et al have shown that Ang II promotes
the conversion of latent TGF-b to the biologically active form
[46]. Further data by Wolf et al indicate that Ang II induces
cellular hypertrophy of cultured murine proximal tubular cells,
and that this process is mediated by the synthesis and activation of
endogenous TGF-b [47]. Thus, it is clear that Ang II also
contributes to the development of tubulointerstitial fibrosis
through a non-hemodynamic mechanism. It is possible that these
non-hemodynamic effects of Ang II may be contributing to the
development of tubulointerstitial apoptosis in our model of CsA
nephropathy.
We also examined the effect of inhibition of NO production
with L-NAME and L-arginine administration in our model of CsA
nephropathy. Previous studies have suggested that renal NO
production in CsA treated animals may act to counteract some of
the vasoconstrictive effects of CsA [12, 13, 48–51]. It is well known
that cyclosporine’s immunosuppressive effects are dependent
upon CsA interaction with its binding protein cyclophilin and
inhibition of the Ca21/calmodulin dependent protein calcineurin.
As a result interleukin (IL)-2 production is inhibited. One possi-
ble explanation for CsA inhibition of nitric oxide has been
proposed by Amore et al in which CsA acting in a similar fashion
via a complex with cyclophilin causes an inhibition of the activity
of the Ca21/calmodulin dependent cNOS in the kidney [12]. In
this study, the blockade of NO with co-administration of CsA led
to worse tubulointerstitial fibrosis and apoptosis. These data are
most consistent with the possibility that blocking NO may act to
potentiate the vasoconstriction and ischemia induced by CsA on
the tubulointerstitium.
Finally, it was of interest that in both protocols the correlation
of fibrosis scores and apoptosis in individual animals revealed a
tight correlation. Previous studies in other models of tubulointer-
stitial injury, such as the remnant kidney model [22] and post-
ureteral obstruction models [52–54] have found an increase in
apoptosis in association with the development of fibrosis. This is
similar to studies in progressive glomerulosclerosis that also show
an excess of apoptosis in the late stages of glomerular scarrring
[22]. The mechanism for this increase in apoptosis is unclear.
However, the possibility that excess apoptosis could be of patho-
genic importance needs to be considered. Such an “undesirable”
engagement of apoptosis leading to the development of renal
scarring has already been proposed by Savill, Mooney and Hughes
[55]. It is well known that renal injury can undergo repair and
remodeling [56, 57]. However, we postulate that loss of cellularity
by excessive apoptosis may prevent the ability of the host to
effectively remodel and repair tissue in areas of injury.
Based on the findings in our studies, we propose a hypothesis
for the consequence of apoptosis in CsA nephropathy (Fig. 8).
Cyclosporine A mediated vasoconstriction has been linked to
activation of the renin-angiotensin system [9–11, 40, 41, 45], to a
direct vasoconstrictive effect [58], endothelin release [58–60],
enhanced sympathetic tone [61, 62] and thromboxane A2 activa-
tion [63], which promote vasoconstriction. There is also evidence
Fig. 7. Relationship between the number of TUNEL 1 cells/mm2 versus
fibrosis: Effect of nitric oxide blockade (protocol #2). This linear regres-
sion shows the significant correlation between apoptosis and interstitial
fibrosis in animals receiving cyclosporine (CsA; 7.5 mg/kg/day) versus CsA
(7.5 mg/kg/day) 1 L-NAME (r 5 0.83, P , 0.0001). These results indicate
that apoptosis and interstitial fibrosis can be potentiated by L-NAME in
this model. Symbols are: (F) CsA 7.5 mg/kg/day; (E) CsA 1 L-Arg; ()
CsA 1 LNAME; () vehicle 1 L-Arg; (f) vehicle 1 L-NAME. r 5 0.83;
P , 0.0001.
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that CsA inhibits vasodilatory mediators such as nitric oxide
[12–13, 48–51], prostaglandins [61] and prostacyclin [64]. It has
also been shown that dopamine agonists and platelet activating
factor antagonists can improve renal hemodynamics in cyclospor-
ine nephrotoxicity [11, 65]. Angiotensin II may also activate
TGF-b via a non-hemodynamic effect as previously described.
Therefore, it appears that there are many mediators that can
promote vasoconstriction and tubulointerstitial injury in the set-
ting of cyclosporine therapy. The result of the activation of these
mediators is ischemia to the tubulointerstitium. This renal isch-
emia may be countered by measures that increase renal blood
flow, such as blocking Ang II formation or binding, or by
stimulating local NO production. We also propose that in the
setting of unopposed or continued tubulointerstitial ischemia
there becomes an imbalance between apoptosis and proliferation
favoring excessive apoptosis and the development of a potentially
irreversible hypocellular and fibrotic lesion.
In conclusion, CsA nephropathy is associated with a marked
increase in apoptosis that is partially mediated by Ang II and NO.
This increase in apoptosis along with increased production of
growth factors such as TGF-b1 and PDGF [66] may act in concert
to promote tubulointerstitial fibrosis. We propose that accelerated
apoptosis could account for the inability of the host to effectively
remodel tissue and thereby play a role in interstitial fibrosis
formation. Further studies are needed to determine how this
proposed pathway, beginning with CsA mediated vasoconstriction
and ischemia and resulting in the formation of a hypocellular
fibrotic kidney, can be interrupted in order to prevent the toxic
effects of chronic CsA exposure.
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APPENDIX
Abbreviations in this article are: Ang II, angiotensin II; CsA, cyclospor-
ine A; F, furosemide; H, hydralazine; L, losartan; L-Arg, L-arginine; NO,
nitric oxide; Tdt, terminal deoxynucleotidyl transferase; TI, tubulointer-
stitial; TUNEL, Tdt-mediated dUTP-biotin nick end labeling method;
VH, vehicle.
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